34 results about "Genus Bifidobacterium" patented technology

The objective of this invention is to provide: aerobic-tolerant Bifidobacterium spp. capable of being cultured under aerobic conditions, a method for culturing the same and a method for screening it, and a composition comprising aerobic-tolerant Bifidobacterium spp. and a method for manufacturing the same. The present invention that solves this problem is a method for culturing Bifidobacterium bacteria, comprising the step of culturing Bifidobacterium bacteria having any one of the following (1) to (7) under aerobic conditions: (1) a gene consisting of a base sequence shown in sequence number 1 or 2; (2) a gene having more than 90% identity with a base sequence shown in sequence number 1 or 2; (3) a gene consisting of a base sequence in which 1 to several bases are missing, substituted, or added to a base sequence shown in sequence number 1 or 2; (4) a gene consisting of a base sequence of DNA that can hybridize under strict conditions with a DNA consisting of a complementary sequence of a base sequence shown in sequence number 1 or 2; (5) a gene consisting of a degenerate isomer of a base sequence shown in sequence number 1 or 2; (6) a gene encoding a protein consisting of an amino acid sequence shown in sequence number 3 or 4; (7) a gene encoding a protein consisting of an amino acid sequence in which 1 to several amino acids are missing, substituted, or added to an amino acid sequence shown in sequence number 3 or 4.

The application provides bifidobacterium longum MG-G763 for improving constipation, and belongs to the technical field of microorganisms. The bifidobacterium longum MG-G763 provided by the application can effectively relieve constipation by integrating multiple effects such as nerve regulation, immune regulation, barrier repair and flora regulation, and systematically restoring intestinal function homeostasis. The bifidobacterium longum MG-G763 can significantly improve the defecation particle number and defecation weight of constipated mice, shorten the time for defecating the first black stool, improve the small intestinal transport rate of the mice, effectively improve and relieve the defecation condition of the constipated mice, and significantly increase the amount of intestinal beneficial bacteria and reduce the amount of harmful bacteria, thereby promoting intestinal health.

The present invention relates to bacteria, compositions and methods for their production, and prebiotic compositions. By the present invention, novel Bifidobacterium bacteria having assimilation ability of two or more HMOs are provided. The bacteria are selected from the group consisting of Bifidobacterium longum subsp. infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058), and Bifidobacterium bifidum (NITE BP-03067).

A cosmetic treatment method comprising application of a composition comprising at least one antioxidant and a Bifidobacterium spp. lysate. The present invention relates to a method for the cosmetic treatment of the scalp and hair comprising application of a composition comprising at least one specific antioxidant, a Bifidobacterium spp. lysate and water. Preferably, the cosmetic treatment method of the present invention is a method for caring for and / or conditioning the scalp and hair.

COMPOSITION AND METHOD FOR THE CARE OF KERATINOUS MATERIALS The present invention relates to a composition, preferably for the care of keratinous materials, comprising: a) at least one microorganism of the species of the genus Bifidobacterium, the microorganism being in lysate form, b) at least one extract of Salvia miltiorrhiza, and c) an extract of Sphingomonas ferment. The present invention also relates to a non-therapeutic method for the care of keratinous materials, comprising the application of said composition to the keratinous materials. Figure for the abstract: none

This chronic kidney disease progression inhibitor utilizes Bifidobacterium bifidum as an active ingredient. As a result, present invention provides an agent that is more effective by using a bacterial strain that is different from hitherto-reported bacteria that belong to the genus Bifidobacterium and that have been used against chronic kidney diseases.

The invention discloses a fluorescent quantitative detection kit for bifidobacteria in intestinal microorganisms and application of the fluorescent quantitative detection kit. The invention provides a complete set of single-stranded DNA for detecting a bifidobacterium strain. The complete set of single-stranded DNA is composed of a primer pair and a single-stranded DNA probe, the primer pair is composed of an upstream primer as shown in SEQ ID No. 1 and a downstream primer as shown in SEQ ID No. 2; the nucleotide sequence of the single-stranded DNA probe is as shown in SEQ ID No. 3. The method is simple and fast in period; the probe method real-time fluorescent quantitative PCR detection is high in targeting property, and the number of bifidobacteria in a sample can be reduced to a greater extent; the primer and the probe group have high specificity, bifidobacterium can be identified in complex intestinal microorganisms, and various strains under the bifidobacterium can be effectively amplified; the qualitative and quantitative detection of bacteria genus can be simultaneously realized, and the quantification is more accurate; according to the detection result, guiding significance is provided for probiotic supplement of the detected person.

Provided is a bacterium belonging to Bifidobacterium pseudocatenuicola, which is capable of using xylan and has excellent survivability in a culture medium containing a milk component. The bacterium belonging to the Bifidobacterium pseudocatenum has a xylanase gene on a genome, and the survivability of the bacterium in a culture medium containing milk components is higher than that of the Bifidobacterium pseudocatenum YIT 11057 (NITE BP-02930).

The invention belongs to the technical field of food, and particularly relates to a nutritional composition for promoting growth of intestinal healthy flora and application of the nutritional composition. Compared with the prior art, the lactoferrin, the calcium, the iron and the zinc in the nutritional composition provided by the invention can promote the abundance of bifidobacterium and the abundance of bifidobacterium breve in the intestinal tracts of infants, the richness and the species number of flora in the intestinal tracts of the infants are remarkably increased, and the flora state closer to that of breast feeding is formed.

A composition, preferably for caring for keratin materials, comprise: a) at least one microorganism of the genus Bifidobacterium species, the microorganism being in the lysate form, b) at least one Salvia miltiorrhiza extract, and c) Sphingomonas ferment extract. A non-therapeutic method for caring for the keratin materials comprises applying the composition to the keratin materials.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

1. An orally administered composition for use in the prevention and / or treatment of degenerative eye diseases, comprising a lysate of probiotic microorganisms in the form of a dry powder of the genera Bacillus, Lactobacillus, Streptococcus, Saccharomyces, and Bifidobacterium.

This invention discloses the use of phytic acid in the preparation of drugs or functional foods for regulating intestinal flora imbalance caused by Streptococcus mutans, belonging to the field of biomedicine and microecological regulation technology. This invention is the first to discover that oral phytic acid can effectively inhibit the abnormal colonization of Streptococcus mutans in the intestine, restore intestinal flora diversity, increase the abundance of beneficial bacteria (such as Bifidobacterium and Lactobacillus), reduce the proportion of pro-inflammatory bacteria, and improve intestinal barrier function and inflammatory status. This invention provides a new strategy for regulating intestinal flora imbalance caused by Streptococcus mutans.

The invention discloses application of pH-ROS dual-response fullerol gel in improvement of intestinal microbiota and colitis, and belongs to the technical field of biological pharmacy. The invention provides an application of pH-ROS dual-response fullerol gel SA-DA / CMCS-FPBA-coated C60 (OH) 12 in treatment of ulcerative colitis by regulating intestinal microbiota. The fullerol gels can treat colitis by promoting a substantial increase in beneficial bacteria of the genus Bifidobacterium, thereby reducing other harmful bacteria and maintaining the levels of probiotics of the genus Shigella, Enterococcus and Fecalis. After being applied, the compound has a potential effect of maintaining the steady state of microorganisms for patients suffering from ulcerative colitis, has the characteristics of low toxicity, high efficiency and the like, and has a good drug development prospect.

The invention belongs to the technical field of microorganisms, and particularly discloses a composition for promoting proliferation of bifidobacterium longum subsp. Infantis i18 and application of the composition. Compared with bifidobacteria such as bifidobacterium breve, bifidobacterium animalis or bifidobacterium longum, the bifidobacterium bifidum i771 has the advantages that the bifidobacterium bifidum i771 is found to be capable of remarkably promoting the proliferation of bifidobacterium infantis i18, so that the composition containing the bifidobacterium bifidum i771 for promoting the proliferation of the bifidobacterium longum subsp.infantis i18 is provided on the basis of the bifidobacterium bifidum i771. Through optimization of the carbon source, the composition with the function of regulating intestinal flora is provided. In the composition, the target strain, the symbiotic strain and the specific carbon source have a remarkable synergistic effect, rapid starting, continuous proliferation and stable maintenance of the target strain can be achieved, the relative abundance of bifidobacterium flora in intestinal tracts is obviously improved, and the intestinal flora structure is promoted to develop towards the healthy direction. The product is suitable for regulating intestinal micro-ecology, and is especially suitable for infants.

[Problem] The purpose of the present invention is to provide: a composition capable of promoting the secretion of serotonin; food or drink, a cosmetic, and a medicine containing the composition; and methods for producing the same. [Solution] Provided is a serotonin secretion-promoting composition containing at least two types of enteric bacteria. In particular, the enteric bacteria are preferably selected from enteric bacteria belonging to the genus Eubacterium, Clostridium, or Bifidobacterium.

Composition comprising at least one microorganism of the genus Bifidobacterium species, a fraction thereof, a metabolite thereof or mixtures thereof, the microorganism(s) being in lysate form; at least one aqueous phase gelled with at least one hydrophilic gelling agent chosen from hydrophilic acrylic homopolymers and amphiphilic acrylic polymers, hyaluronic acid and / or a derivative thereof, at least one polyol, and at least one fatty phase comprising at least one non-volatile oil; and the cosmetic use thereof.

The invention discloses a promoter library applicable to bifidobacterium breve and application, and belongs to the technical field of genetic engineering and microbial engineering. According to the invention, a promoter PC9 with bidirectional transcription characteristics and an inducible promoter responding to linoleic acid are obtained through screening. Wherein the promoter PC3-LA can obviously respond to the LA to improve the activity, and the PB5 has the strongest activity. The invention also constructs a promoter library with gradient intensity, can realize controllable expression of target protein in bifidobacterium microorganisms, provides an element for promoter engineering of bifidobacterium breve, and has wide application value.

Vegan protein powder, characterized in that the protein powder contains at least rice protein, pea protein, a prebiotic, an amino acid, a probiotic of the genus Bifidobacterium and a probiotic of the genus Lactobacillus, wherein the vegan protein powder is free of sweeteners.

The invention belongs to the technical field of food, and particularly relates to infant formula milk powder. Compared with the prior art, the infant milk powder provided by the invention can promote the growth and development of infants, improve the comfort level of intestinal tracts, reduce the index score of feeding difficulty, promote the abundance of bifidobacterium and bifidobacterium breve in the intestinal tracts of the infants, remarkably increase the richness and species number of flora in the intestinal tracts of the infants, and improve the immunity of the infants. And a flora state closer to that of breast feeding is formed.

Provided is a method for efficiently transforming a bacterium belonging to the genus Bifidobacterium. The present invention is a method for transforming a bacterium belonging to the genus Bifidobacterium, which comprises bringing a bacterium belonging to the genus Bifidobacterium, which is a receptor, into contact with a bacterium, which is a donor containing DNA introduced into the receptor, or a linear DNA, and carrying out standing culture, the culture medium for the standing culture being a culture medium having a pH of 6.0 or more and less than 10.0; the content x (mass%) of saccharides that can be assimilated by a bacterium belonging to the genus Bifidobacterium, which is the receptor, satisfies 0 < x < = 0.2 * (pH)-1.2 when the pH is 6.0 or more and less than 8.5, and satisfies 0.2 * (pH)-1.7 < x < = 0.2 * (pH)-1.2 when the pH is 8.5 or more and less than 10.0.

A method of treatment and use of probiotic compositions in treatment of weight loss-related conditions in wasting, and cachexia, includes the steps of administering a probiotic composition to a subject deemed in need of such treatment wherein the composition includes at least two bacteria, each preferably selected from a different genus, the genera preferably selected from the group Lactobacillus spp, Enterococcus spp, and Bifidobacterium spp, and a probiotic composition for use in treatment of a subject having a weight loss-related condition wherein the composition includes at least two bacteria, each preferably selected from a different genus, the genera preferably selected from the group Lactobacillus spp, Enterococcus spp, and Bifidobacterium spp.

An object of the present invention is to provide an agent for improving intestinal flora that can increase the numbers of bacteria of genus Bifidobacterium and bacteria of genus Lactobacillus in the intestine to improve the intestinal flora. (i) A lipase derived from a koji mold and / or (ii) a cellulase can increase the numbers of both bacteria of genus Bifidobacterium and bacteria of genus Lactobacillus in the intestine to exert an excellent effect of improving the intestinal flora.

The application discloses Bifidobacterium breve and application thereof in relieving Alzheimer's disease and belongs to the technical field of probiotics. 18 Bifidobacterium strains are separated from the feces of children aged 0-3 years old, and are identified as Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium animalis through analysis and identification. A Bifidobacterium breve LE4 strain with potential ability of relieving Alzheimer's disease is screened out through in-vitro antioxidant and LPS clearance capacity screening. Through behavior experiment (nest building experiment, open field experiment, water maze experiment), histopathological analysis, molecular biology detection and other methods, the LE4 strain is comprehensively evaluated to have the effects of improving cognitive function, reducing Aβ deposition and tau protein phosphorylation, reducing neural inflammation, enhancing synaptic plasticity, repairing intestinal barrier, regulating intestinal flora and metabolites and other multi-target point intervention AD, and provides a new strategy for promoting AD microecological treatment.

The invention provides a breast milk oligosaccharide compound and application of the breast milk oligosaccharide compound in preparation of a composition for improving intestinal homeostasis. The breast milk oligosaccharide compound comprises a bifidobacterium strain, one or more breast milk oligosaccharides, whey protein and aromatic amino acid, and the bifidobacterium strain is selected from bifidobacterium longum or bifidobacterium bifidum; the aromatic amino acid is selected from phenylalanine or tryptophan. The breast milk oligosaccharide compound promotes growth of specific probiotics and generation of aromatic amino acid metabolites, so that the establishment of the intestinal homeostasis of infants as early as possible is promoted, and the infection risk of the infants in the period is reduced.

Composition comprising at least one microorganism of the genus Bifidobacterium species, one of its fractions, one of its metabolites or mixtures thereof, the microorganism(s) being in lysate form; at least one aqueous phase gelled by at least one hydrophilic gelling agent selected from hydrophilic acrylic homopolymers and amphiphilic acrylic polymers, hyaluronic acid and / or one of its derivatives, at least one polyol, and at least one oily phase comprising at least one non-volatile oil; and its use in cosmetics.

The present application relates to a kind of synbiotic preparation, comprising: probiotic or its bacterial lysate, fermentation product, wherein probiotic is one or more selected from the following group: Bifidobacterium, Streptococcus, Lactobacillus, Saccharomycete, Escherichia coli;Prebiotic is one or more selected from the following group: breast milk oligosaccharide, fructo-oligosaccharide, inulin, lactulose, galacto-oligosaccharide, soybean oligosaccharide, resistant dextrin, xylo-oligosaccharide, isomalto-oligosaccharide, chitooligosaccharide;And wall material;The probiotic or its bacterial lysate, fermentation product is coupled with prebiotic, and wall material is wrapped in the coupling product.The synbiotic preparation of the application is simple, no chemical drug or antibiotic component is added, can repair damaged intestinal mucosal barrier, reduce intestinal permeability, regulate immune balance, optimize flora structure, so as to more effectively treat colitis.In addition, it is convenient to use, easy to promote in farm.

The invention discloses application of bacteroides xylanolyticum capable of promoting intestinal bacteria to produce propionic acid and a composition of the bacteroides xylanolyticum in relieving ulcerative colitis, and belongs to the technical field of microorganisms. The bacteroides xylanolyticus NSP016 disclosed by the invention can quickly utilize konjac glucomannan, and the composition of the bacteroides xylanolyticus and konjac glucomannan can improve the rise of histopathologic score of mice with ulcerative colitis, maintain the integrity of intestinal barriers, reduce the oxidative stress level and remarkably reduce the level of clinical diagnosis markers of colitis, so that the clinical diagnosis of colitis is facilitated. The effect is better than that of a clinical medicine mesalazine. The bacteroides xylanolyticum NSP016 and the composition thereof disclosed by the invention have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.

This invention relates to a method of identifying a subject having an increased probability of having a beneficial clinical response to administration of a bacterial strain of the genus Bifidobacterium or a mixture of two or more strains thereof to said subject, by measuring the level of some specific biomarkers in said subject.

The invention belongs to the technical field of microorganisms, and particularly discloses application of bifidobacterium longum subsp. Infantis i18 in preparation of products for improving intestinal microecology of caesarean section infants. The bifidobacterium longum subsp. Infantis i18 is found to have excellent intestinal tract colonization ability, and the strain can significantly improve the relative abundance of beneficial microbial communities such as lactobacillus, bacteroides and bifidobacterium in the intestinal tract of a caesarean section infant in the early stage, and effectively inhibit colonization of harmful bacteria such as klebsiella. The bacterium is combined with breast milk oligosaccharides, especially compounded with 2 '-FL and LNnT, so that directional colonization of beneficial flora in the intestinal tract of the newborn can be induced through synergistic interaction, the abundance of the beneficial flora is remarkably improved, meanwhile, the load of harmful flora is reduced, effective intervention on the intestinal flora structure of the cesarean section infant is achieved, and the intestinal tract of the newborn infant is protected. And the rapid development towards the normal delivery infant intestinal flora mode is promoted, so that the intestinal barrier function and the immunity of the cesarean delivery newborn are improved, and the potential health risk is reduced.